Stem cell delivery of therapies for brain disorders
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
The blood brain barrier (BBB) poses a problem to deliver drugs for brain malignancies and neurodegenerative disorders. Stem cells such as neural stem cells (NSCs) and mesenchymal stem cells (MSCs) can be used to delivery drugs or RNA to the brain. This use of methods to bypass the hurdles of delivering drugs across the BBB is particularly important for diseases with poor prognosis such as glioblastoma multiforme (GBM). Stem cell treatment to deliver drugs to neural tumors is currently in clinical trial. This method, albeit in the early phase, could be an advantage because stem cells can cross the BBB into the brain. MSCs are particularly interesting because to date, the experimental and clinical evidence showed ‘no alarm signal’ with regards to safety. Additionally, MSCs do not form tumors as other more primitive stem cells such as embryonic stem cells. More importantly, MSCs showed pathotropism by migrating to sites of tissue insult. Due to the ability of MSCs to be transplanted across allogeneic barrier, drug‐engineered MSCs can be available as off‐the‐shelf cells for rapid transplantation. This review discusses the advantages and disadvantages of stem cells to deliver prodrugs, genes and RNA to treat neural disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ren, G., Zhang, L., Zhao, X., Xu, G., Zhang, Y., Roberts, A. I., Zhao, R. C., & Shi, Y. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2007.11.014 · Cited by 2,101
Neurotrophic and Neurotoxic Effects of Amyloid β Protein: Reversal by Tachykinin Neuropeptides
Yankner, B. A., Duffy, L. K., & Kirschner, D. A. (1990) · Science · doi:10.1126/science.2218531 · Cited by 1,975
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease
Gómez‐Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., Parisi, J. E., & Hyman, B. T. (1997) · Annals of Neurology · doi:10.1002/ana.410410106 · Cited by 1,489
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442
Silber, J., Lim, D. A., Petritsch, C., Persson, A. I., Maunakea, A. K., Yu, M., Vandenberg, S. R., Ginzinger, D. G., James, C. D., Costello, J. F., et al. (2008) · BMC Medicine · doi:10.1186/1741-7015-6-14 · Cited by 957
Exosomes are released by cultured cortical neurones
Fauré, J., Lachenal, G., Court, M., Hirrlinger, J., Chatellard-Causse, C., Blot, B., Grange, J., Schoehn, G., Goldberg, Y., Boyer, V., et al. (2006) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2005.12.003 · Cited by 896
Ramasamy, R., Lam, E. W.-F., Soeiro, I., Tisato, V, Bonnet, D., & Dazzi, F. (2007) · Leukemia · doi:10.1038/sj.leu.2404489 · Cited by 404
Qiao, L., Xu, Z.-L., Zhao, T.-J., Ye, L.-H., & Zhang, X.-D. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.04.032 · Cited by 313
miR-9: a versatile regulator of neurogenesis
Coolen, M., Katz, S., & Bally-Cuif, L. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00220 · Cited by 306
Therapeutic potential of mesenchymal stromal cells in a mouse breast cancer metastasis model
Sun, B., Roh, K.-H., Park, J.-R., Lee, S.-R., Park, S.-B., Jung, J.-W., Kang, S.-K., Lee, Y.-S., & Kang, K.-S. (2009) · Cytotherapy · doi:10.1080/14653240902807026 · Cited by 214
Cited by
Bliss, S. A., Sinha, G., Sandiford, O. A., Williams, L. M., Engelberth, D. J., Guiro, K., Isenalumhe, L. L., Greco, S. J., Ayer, S., Bryan, M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1092 · Cited by 383
Self-citationRegenerative Stem Cell Therapy for Neurodegenerative Diseases: An Overview
Sivandzade, F., & Cucullo, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042153 · Cited by 224
“MSCs do not organize tumors like other primitive stem cells, such as ESCs [25].”
BackgroundA Historical Review of Brain Drug Delivery
Pardridge, W. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061283 · Cited by 219
Cell encapsulation: Overcoming barriers in cell transplantation in diabetes and beyond
Farina, M., Alexander, J. F., Thekkedath, U., Ferrari, M., & Grattoni, A. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.04.018 · Cited by 192
Clavreul, A., Pourbaghi-Masouleh, M., Roger, E., Lautram, N., Montero-Menei, C. N., & Menei, P. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0605-2 · Cited by 35
Metadata
- Authors
- Aleynik, A., Gernavage, K. M., Mourad, Y. S., Sherman, L. S., Liu, K., Gubenko, Y. A., & Rameshwar, P.
- Venue
- Clinical and Translational Medicine
- Publisher
- Wiley
- Published
- 2014-07-19
- Volume
- 3
- Issue
- 1
- Pages
- 24-24
- ISSN
- 2001-1326 (ISSN-L)
- OpenAlex
- W2106081613
- Cited by
- 101
- References
- 11
- FWCI
- 6.00
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Stem cell delivery of therapies for brain disorders. https://app.cochat.ai/papers/10.1186/2001-1326-3-24
- The paper
- Aleynik, A., Gernavage, K. M., Mourad, Y. S., Sherman, L. S., Liu, K., Gubenko, Y. A., & Rameshwar, P. (2014). Stem cell delivery of therapies for brain disorders. Clinical and Translational Medicine. https://doi.org/10.1186/2001-1326-3-24
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.